| 摘要 |
<p>In vitro detection, early detection, differentiation, progress monitoring and/or evaluation of pathophysiological conditions of a patient, where the pathophysiological conditions are e.g. systemic inflammatory response syndrome (SIRS), comprises (a) isolation of sample nucleic acids from a sample derived from a patient; (b) determination of gene activity by a large number of at least three polynucleotides comprising e.g. M15, M16 or M17; (c) determination of gene activity of at least one internal reference gene; and (d) forming a value from the individually determined gene activities. In vitro detection, early detection, differentiation, progress monitoring and/or evaluation of pathophysiological conditions of a patient, where the pathophysiological conditions are: systemic inflammatory response syndrome (SIRS), sepsis and its degrees of severity; sepsis-like conditions, septic shock, bacteremia, infective/non-infectious multiorgan failure, early detection of these conditions; focus control, control of surgical rehabilitation of the infection focus; responders/non-responders for a specific therapy, treatment monitoring; distinction between infectious and non-infectious etiology of systemic reactions of the organism, such as SIRS, sepsis, postoperative complications, chronic and/or acute organ dysfunction, shock response, inflammatory response and/or trauma, comprises (a) isolation of sample nucleic acids from a sample derived from a patient; (b) determination of gene activity by a large number of at least three polynucleotides comprising M2, M3, M4, M6, M7, M8, M9, M10, M12, M13, M15, M16 or M17, and/or their isoforms, gene loci, transcripts and/or fragments with a length of at least 5 nucleotides, for forming at least one characteristic multi-gene biomarker for recording, differentiation and/or the progression of pathophysiological conditions of a patient, where the polynucleotides are given in table of the specification; (c) determination of gene activity of at least one internal reference gene to which the gene activities under (b) can be referenced, preferably normalized; and (d) forming a value from the individually determined gene activities of the multi-gene biomarker, which indicates the pathophysiological condition. Independent claims are included for: (1) use of at least three polynucleotides for forming at least one of multi-gene biomarkers for producing a multiplex assay as a tool for in vitro detection, early detection, differentiation, progress monitoring and/or evaluation of pathophysiological conditions of a patient; (2) primers for carrying out the above method, where the primers are given in table of the specification; and (3) a kit for carrying out the above method, comprising at least one multi-gene biomarker.</p> |
